Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder
ICD-10 F13.182 is a billable code used to indicate a diagnosis of sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder.
F13.182 refers to a condition characterized by the abuse of sedative, hypnotic, or anxiolytic substances, leading to a sleep disorder induced by these substances. Patients may misuse medications such as benzodiazepines or barbiturates, resulting in dependence and withdrawal symptoms. The sleep disorder can manifest as insomnia, excessive daytime sleepiness, or altered sleep architecture. Clinicians must assess the severity of substance use, the impact on daily functioning, and any co-occurring mental health disorders. Treatment often involves a multidisciplinary approach, including detoxification, cognitive-behavioral therapy, and support groups. Accurate diagnosis and coding are essential for effective treatment planning and insurance reimbursement.
Comprehensive assessment of substance use history, mental status examination, and treatment plan.
Patients presenting with anxiety disorders who misuse anxiolytics, or those with insomnia related to sedative abuse.
Consideration of dual diagnosis and the need for integrated treatment approaches.
Detailed substance use assessment, including frequency, quantity, and impact on functioning.
Patients undergoing detoxification from sedatives or those in outpatient treatment programs.
Focus on harm reduction strategies and long-term recovery planning.
Used for follow-up visits in patients with substance use disorders.
Document the patient's substance use history, treatment response, and any changes in medication.
Psychiatry may require additional mental health assessments.
F13.182 includes a specific sleep disorder induced by sedative, hypnotic, or anxiolytic abuse, while F13.180 does not involve a sleep disorder.
